Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies
| Autor: | Todd A. Katz, Mark C Gillies, Yuichiro Ogura, Chengxing Lu, Carola Metzig, Edoardo Midena |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Post hoc Article Subject genetic structures Diabetic macular edema MEDLINE law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial lcsh:Ophthalmology law Ophthalmology medicine In patient 030212 general & internal medicine Baseline (configuration management) Aflibercept business.industry Retinal eye diseases chemistry lcsh:RE1-994 030221 ophthalmology & optometry Clinical Study business medicine.drug |
| Zdroj: | Journal of Ophthalmology Journal of Ophthalmology, Vol 2018 (2018) |
| ISSN: | 2090-004X |
| Popis: | Purpose. To report the impact of baseline central retinal thickness (CRT) on outcomes in patients with diabetic macular edema (DME) in VIVID-DME and VISTA-DME. Methods. Post hoc analyses of two randomized controlled trials in which 862 DME patients were randomized 1 : 1 : 1 to treatment with intravitreal aflibercept 2.0 mg every 4 weeks (2q4), intravitreal aflibercept 2.0 mg every 8 weeks after five initial monthly doses (2q8), or macular laser photocoagulation at baseline and as needed. We compared visual and anatomical outcomes in subgroups of patients with baseline CRT μm and ≥400 μm. Results. At weeks 52 and 100, outcomes with intravitreal aflibercept 2q4 and 2q8 were superior to those in laser control-treated patients regardless of baseline CRT. When looked at in a binary fashion, the treatment effect of intravitreal aflibercept versus laser was not significantly better in the ≥400 μm than the μm group; when looked at as a continuous variable, baseline CRT seemed to have an impact on the treatment effect of intravitreal aflibercept versus laser. Conclusions. Post hoc analyses of VIVID-DME and VISTA-DME demonstrated the benefits of intravitreal aflibercept treatment in DME patients with baseline CRT μm and ≥400 μm. This trial is registered with NCT01331681 and NCT01363440. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text